Let the games begin!
Now that all the major diabetes tech companies have reported it’s safe to say two things.
1. Ozempic is NOT killing diabetes tech.
2. Consolidation is next on the agenda.
It’s the second point that needs to examined further. As we noted last week Tandem most likely will be the catalyst for the coming consolidation. With a market cap of just over $1 Billion, sitting on almost $500 million in cash and an installed user base of approximately 440,000 the company is there for the taking. As we have noted previously the smart . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.